NCT06346600 A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
| NCT ID | NCT06346600 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Skyline Therapeutics |
| Condition | Neovascular (Wet) Age-related Macular Degeneration |
| Study Type | OBSERVATIONAL |
| Enrollment | 83 participants |
| Start Date | 2024-04-02 |
| Primary Completion | 2031-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 83 participants in total. It began in 2024-04-02 with a primary completion date of 2031-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility Criteria
Inclusion Criteria: Subjects who only meet all of the following criteria are eligible for this study: * nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; * Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study Exclusion Criteria: * Subjects who are judged by the investigator unsuitable for this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06346600 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Neovascular (Wet) Age-related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06346600 currently recruiting?
Yes, NCT06346600 is actively recruiting participants. Contact the research team at yongqin.wang@skytx.com for enrollment information.
Where is the NCT06346600 trial being conducted?
This trial is being conducted at Boston, United States, Katy, United States, Norfolk, United States, Hefei, China and 6 additional locations.
Who is sponsoring the NCT06346600 clinical trial?
NCT06346600 is sponsored by Skyline Therapeutics. The trial plans to enroll 83 participants.